
    
      In the 28-week treatment phase, participants were randomized to receive either infliximab
      plus naproxen or placebo plus naproxen.

      After 28-weeks of treatment, participants that achieved partial remission in the treatment
      phase were randomized to continued treatment with naproxen or to receive no treatment and
      were followed for an additional 24 weeks (follow-up phase).
    
  